Washington Examiner September 4, 2023
By Mary Vought

The Biden administration recently announced the next step toward socialized medicine, releasing its list of 10 prescription drugs subject to “negotiation” with the Medicare program. As one might expect from this administration, its latest gambit, while being couched in market-oriented language, will only further entrench the government in its control of the healthcare system.

Under the rubric laid out by Democrats’ mistitled Inflation “Reduction” Act last year, this “negotiation” will result in a predetermined outcome. The law specifies that drug companies will receive a “maximum fair price” that is at least 25%-60% below current market rates. Thus, the “negotiations” required by the law are little more than a charade designed to give the appearance of a give-and-take process, when in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
What a Trump presidency could mean for ASCs: 4 leaders weigh in
How 'Make America Healthy Again' May Have Found Its Moment
Mercy takes to Capitol Hill on AI
Shorter surgeon wait times, fewer ED visits: 11 Biden Cancer Moonshot updates
Biden administration pushes anti-obesity drug pressure to Trump

Share This Article